Skip to main content

Research Repository

Advanced Search

Outputs (9)

Anticancer innovative therapy : highlights from the ninth annual meeting (2019)
Journal Article
Volpari, T., De Santis, F., Bracken, A., Pupa, S., Buschbeck, M., Wegner, A., …Di Nicola, M. (2020). Anticancer innovative therapy : highlights from the ninth annual meeting. Cytokine and Growth Factor Reviews, 51, 1-9. https://doi.org/10.1016/j.cytogfr.2019.12.002

The Ninth Annual Conference of “Anticancer Innovative Therapy”, organized by Fondazione IRCCS Istituto Nazionale dei Tumori di Milano (Fondazione IRCCS INT) and hosted by Hotel Michelangelo, was held in Milan on 25 January 2019. Cutting-edge science... Read More about Anticancer innovative therapy : highlights from the ninth annual meeting.

Hypoxia and hyperglycaemia determine why some endometrial tumours fail to respond to metformin (2019)
Journal Article
Sivalingam, V., Latif, A., Kitson, S., McVey, R., Finegan, K., Marshall, K., …Crosbie, E. (2020). Hypoxia and hyperglycaemia determine why some endometrial tumours fail to respond to metformin. British Journal of Cancer, 122(1), 62-71. https://doi.org/10.1038/s41416-019-0627-y

High expression of Ki67, a proliferation marker, is associated with reduced endometrial cancer-specific survival. Pre-surgical metformin reduces tumour Ki-67 expression in some women with endometrial cancer. Metformin's anti-cancer activity may relat... Read More about Hypoxia and hyperglycaemia determine why some endometrial tumours fail to respond to metformin.

FoxO3a as a positive prognostic marker and a therapeutic target in Tamoxifen-resistant breast cancer (2019)
Journal Article
Pellegrino, M., Rizza, P., Donà, A., Nigro, A., Ricci, E., Fiorillo, M., …Morelli, C. (2019). FoxO3a as a positive prognostic marker and a therapeutic target in Tamoxifen-resistant breast cancer. Cancers, 11(12), e1858. https://doi.org/10.3390/cancers11121858

Background: Resistance to endocrine treatments is a major clinical challenge in the management of estrogen receptor positive breast cancers. Although multiple mechanisms leading to endocrine resistance have been proposed, the poor outcome of this sub... Read More about FoxO3a as a positive prognostic marker and a therapeutic target in Tamoxifen-resistant breast cancer.

Dodecyl-TPP Targets Mitochondria and Potently Eradicates Cancer Stem Cells (CSCs): Synergy With FDA-Approved Drugs and Natural Compounds (Vitamin C and Berberine). (2019)
Journal Article
De Francesco, E., Ozsvari, B., Sotgia, F., & Lisanti, M. (2019). Dodecyl-TPP Targets Mitochondria and Potently Eradicates Cancer Stem Cells (CSCs): Synergy With FDA-Approved Drugs and Natural Compounds (Vitamin C and Berberine). Frontiers in Oncology, 9, 615. https://doi.org/10.3389/fonc.2019.00615

Elevated mitochondrial biogenesis and/or metabolism are distinguishing features of cancer cells, as well as Cancer Stem Cells (CSCs), which are involved in tumor initiation, metastatic dissemination, and therapy resistance. In fact, mitochondria-impa... Read More about Dodecyl-TPP Targets Mitochondria and Potently Eradicates Cancer Stem Cells (CSCs): Synergy With FDA-Approved Drugs and Natural Compounds (Vitamin C and Berberine)..

Mitochondrial and ribosomal biogenesis are new hallmarks of stemness, oncometabolism and biomass accumulation in cancer : mito-stemness and ribo-stemness features (2019)
Journal Article
Peiris-Pagès, M., Ozsvari, B., Sotgia, F., & Lisanti, M. (2019). Mitochondrial and ribosomal biogenesis are new hallmarks of stemness, oncometabolism and biomass accumulation in cancer : mito-stemness and ribo-stemness features. Aging, 11(14), 4801-4835. https://doi.org/10.18632/aging.102054

Using proteomics analysis, we previously compared MCF7 breast cancer cells grown as 3D tumor spheres, with the same cell line grown as monolayers. Our results indicated that during 3D anchorage‐independent growth, the cellular machinery associated wi... Read More about Mitochondrial and ribosomal biogenesis are new hallmarks of stemness, oncometabolism and biomass accumulation in cancer : mito-stemness and ribo-stemness features.

Doxycycline, Azithromycin and vitamin C (DAV) : a potent combination therapy for targeting mitochondria and eradicating cancer stem cells (CSCs) (2019)
Journal Article
Fiorillo, M., Tóth, F., Sotgia, F., & Lisanti, M. (2019). Doxycycline, Azithromycin and vitamin C (DAV) : a potent combination therapy for targeting mitochondria and eradicating cancer stem cells (CSCs). Aging, 11(8), 2202-2216. https://doi.org/10.18632/aging.101905

Here, we devised a new strategy for eradicating cancer stem cells (CSCs), via a "synthetic-metabolic" approach, involving two FDA-approved antibiotics and a dietary vitamin supplement. This approach was designed to induce a "rho-zero-like" phenotype... Read More about Doxycycline, Azithromycin and vitamin C (DAV) : a potent combination therapy for targeting mitochondria and eradicating cancer stem cells (CSCs).

Hallmarks of the cancer cell of origin : comparisons with "energetic" cancer stem cells (e-CSCs) (2019)
Journal Article
Sotgia, F., Fiorillo, M., & Lisanti, M. (2019). Hallmarks of the cancer cell of origin : comparisons with "energetic" cancer stem cells (e-CSCs). Aging, 11(3), 1065-1068. https://doi.org/10.18632/aging.101822

Here, we discuss the expected hallmark(s) of the cancer cell of origin and how this may be related to a new tumor cell phenotype, namely "energetic" cancer stem cells (e-CSCs). e-CSCs show many features that would be characteristic of the cancer cell... Read More about Hallmarks of the cancer cell of origin : comparisons with "energetic" cancer stem cells (e-CSCs).

“Energetic” cancer stem cells (e-CSCs) : a new hyper-metabolic and proliferative tumor cell phenotype, driven by mitochondrial energy (2019)
Journal Article
Fiorillo, M., Sotgia, F., & Lisanti, M. (2019). “Energetic” cancer stem cells (e-CSCs) : a new hyper-metabolic and proliferative tumor cell phenotype, driven by mitochondrial energy. Frontiers in Oncology, 8(677), https://doi.org/10.3389/fonc.2018.00677

Here, we provide the necessary evidence that mitochondrial metabolism drives the anchorage-independent proliferation of CSCs. Two human breast cancer cell lines, MCF7 [ER(+)] and MDA-MB-468 (triple-negative), were used as model systems. To
directly... Read More about “Energetic” cancer stem cells (e-CSCs) : a new hyper-metabolic and proliferative tumor cell phenotype, driven by mitochondrial energy.